- Home
- BVFL vs CGEN Comparison
BVFL vs CGEN Comparison
Compare BVFL & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BVFL | CGEN |
|---|---|---|
| Founded | 1873 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6M | 191.1M |
| IPO Year | 2023 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BVFL | CGEN |
|---|---|---|
| Price | $21.30 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 11.9K | ★ 234.7K |
| Earning Date | 04-24-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.19 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $163.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.60 | $1.30 |
| 52 Week High | $22.17 | $3.24 |
Technical Indicators
Market Signals| Indicator | BVFL | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 53.18 |
| Support Level | $20.27 | $2.20 |
| Resistance Level | $22.00 | $2.54 |
| Average True Range (ATR) | 0.66 | 0.12 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 52.66 | 73.68 |
Price Performance
Historical ComparisonAbout BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.